Navigation Links
Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
Date:6/4/2008

o antibodies. Characteristics of aptamers include high specificity and affinity, and the ability to target protein-protein interactions.

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions. Data from the Phase 1 trial and preclinical studies suggest that NU172 has the potential for predictable anticoagulant effects, rapid onset and offset of action, and avoidance of thrombocytopenia.

About Nuvelo and Archemix's Joint Collaborative Effort

In August 2006, Nuvelo expanded its collaboration with Archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, Archemix is responsible for discovery of short-acting aptamers for use in medical procedures, and Nuvelo leads development and worldwide commercialization of these aptamers.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
2. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
3. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
6. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... 2014 Summary Global Markets Direct,s, ,Arbor ... provides an overview of the Arbor Pharmaceuticals, LLC.,s ... provides comprehensive information on the current therapeutic developmental ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals ... VRX) today announced that the company,s Bridgewater, ... from the U.S. Food and Drug Administration (FDA) relating ... records with regards to Sculptra Aesthetic injectable, which was ... Letter pertains to the management of Valeant,s contract manufacturers (rather ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Inc. (OTCQX: DATA), a technology and services company ... trials industry, today announced its participation in the ... will address significant milestones made throughout the pharmaceutical ... technologies are delivering. The EuroMeeting will be held ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... launch of its new formulation of Acetadote ® ... treat acetaminophen poisoning. The proprietary new formulation, which does ... other stabilization or chelating agents, is now stocked at ...
Cached Medicine Technology:DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2New Acetadote® Formulation Now Available in the U.S. 2New Acetadote® Formulation Now Available in the U.S. 3New Acetadote® Formulation Now Available in the U.S. 4
(Date:9/30/2014)... potential for doctors to measure damaging "brain tsunamis" ... moved a step closer to reality, thanks to ... Neuroscience Institute. , The research team, led by ... department of neurosurgery at the UC College of ... spread through an injured brain like tsunami wavescan ...
(Date:9/30/2014)... Sleep apnea is a potential health risk for millions of ... behind the disorder: a "fat" tongue. "This is the ... the tongue of obese patients with obstructive sleep apnea," study ... at the University of Pennsylvania Medical Center, said in a ... findings Oct. 1. Sleep apnea is a common disorder ...
(Date:9/30/2014)... Autism is no stranger to the children of ... is access to clinical services, including reliable diagnosis and ... example, validated for use in Swahili, a major language ... researchers at Brown University and the University of Georgia ... implemented at two sites in the country and found ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... often forces older adults to give up things ... the ability to exercise and participate in physical ... for Eldercare and Rehabilitation Technology (CERT) are working ... developing and evaluating motion-capture technology that monitors the ...
... than placebo, study finds , , TUESDAY, June 10 (HealthDay News) ... disorder (ADHD) in children, a new study finds. , ... of the American Medical Association , the study compared St. ... 17 and found the herb wasn,t any more effective than ...
... June 10 Sen. Olympia Snowe,(R-ME), member of ... -- S.3101 -- that includes pharmacy-related provisions to ... claims and delay the,implementation of Medicaid reimbursement cuts ... owner of Waltz Pharmacy Inc. in,Camden, ME and ...
... Sen. Gordon Smith,(R-OR), member of the ... includes pharmacy-related provisions to provide prompt,payment of ... delay the,implementation of Medicaid reimbursement cuts for ... National Community Pharmacists,Association (NCPA) past president from ...
... NEW YORK, June 10 Ask any entertainment or ... it,s at. And, while watching,your favorite TV show in ... technology just might., (See video from Siemens ... Biograph HD PET-CT system from Siemens is the world,s ...
... SAN DIEGO and MCLEAN, Va., June 10 SAIC, Inc.,(NYSE: ... William Blair Annual,Growth Stock Conference in Chicago on June 18, ... at 3:10 p.m. Central., A live audio webcast of ... site ( http://investors.saic.com ) and an audio,replay of the event ...
Cached Medicine News:Health News:MU researchers enhancing motion-capture technology to benefit older adults 2Health News:St. John's Wort Doesn't Work for ADHD 2Health News:St. John's Wort Doesn't Work for ADHD 3Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:Oregon Community Pharmacy Owner Thanks Sen. Smith for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:SAIC to Webcast Presentation at William Blair Growth Stock Conference 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... of the system is the Nightingale Master Patient ... central monitoring station for the Nightingale Monitoring System. ... Nightingale PPM bedside patient monitors, allowing a clinician ... at once., ,The MPC is a Windows ...
... Signs Monitor 300 Series enhances your productivity ... and after procedures. This easy to use ... readings fast and convenient., ,The Vital ... noninvasive blood pressure monitor with the flexibility ...
... The Welch Allyn Atlas monitor is ... conscious sedation, IV anesthesia procedures, and surgery. ... LED numerics that are visible from across ... to learn how to operate the monitor ...
Medicine Products: